Construction of a Cancer Stem Cell Marker Genes-Related 22-Gene Signature for Overall Survival Prediction in High-Risk Wilms’ Tumor

References

• Davidoff AM. Wilms tumor. Adv Pediatr. 2012;59(1):247–67.
   PubMedGoogle Scholar
• Treger TD, Chowdhury T, Pritchard-Jones K, Behjati S. The genetic changes of Wilms tumour. Nat Rev Nephrol. 2019;15(4):240–51.
   PubMed Web of Science ®Google Scholar
• Varun BR, Jayanthi P, Ramani P. Cancer stem cells: a comprehensive review on identification and therapeutic implications. J Oral Maxillofac Pathol. 2020;24(1):190. Epub 2020/06/09.
   PubMedGoogle Scholar
• Petrosyan A, Villani V, Aguiari P, Thornton ME, Wang Y, Rajewski A, Zhou S, Cravedi P, Grubbs BH, De Filippo RE, et al. Identification and characterization of the Wilms tumor cancer stem cell. Adv Sci (Weinh). 2023;10(20):e2206787. Epub 20230428.
   PubMedGoogle Scholar
• Raved D, Tokatly-Latzer I, Anafi L, Harari-Steinberg O, Barshack I, Dekel B, Pode-Shakked N. Blastemal NCAM+ALDH1+ Wilms’ tumor cancer stem cells correlate with disease progression and poor clinical outcome: a pilot study. Pathol Res Pract. 2019;215(8):152491. Epub 20190610.
   PubMed Web of Science ®Google Scholar
• Hontecillas-Prieto L, García-Domínguez DJ, García-Mejías R, Ramírez-Villar GL, Sáez C, de Álava E. HMGA2 overexpression predicts relapse susceptibility of blastemal Wilms tumor patients. Oncotarget. 2017;8(70):115290–303. Epub 20171214.
   PubMedGoogle Scholar
• Pode-Shakked N, Metsuyanim S, Rom-Gross E, Mor Y, Fridman E, Goldstein I, Amariglio N, Rechavi G, Keshet G, Dekel B, et al. Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population. J Cell Mol Med. 2009;13(8B):1792–808.
   PubMed Web of Science ®Google Scholar
• Qian Y, Daza J, Itzel T, Betge J, Zhan T, Marmé F, Teufel A. Prognostic cancer gene expression signatures: current status and challenges. Cells. 2021;10(3):648. Epub 20210315.
   PubMed Web of Science ®Google Scholar
• Gadd S, Huff V, Walz AL, Ooms AHAG, Armstrong AE, Gerhard DS, Smith MA, Auvil JMG, Meerzaman D, Chen Q-R, et al. A Children’s Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat Genet. 2017;49(10):1487–94. Epub 20170821.
   PubMed Web of Science ®Google Scholar
• Walz AL, Ooms A, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman D, Chen Q-R, Hsu CH, Yan C, et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell. 2015;27(2):286–97.
   PubMed Web of Science ®Google Scholar
• Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, Grundy PE, Malogolowkin M, Beckwith JB, Shamberger RC, et al. Treatment of anaplastic histology Wilms’ tumor: results from the fifth National Wilms’ Tumor Study. J Clin Oncol. 2006;24(15):2352–8.
   PubMed Web of Science ®Google Scholar
• Firdous S, Ghosh A, Saha S. BCSCdb: a database of biomarkers of cancer stem cells. Database (Oxford)). 2022;2022:baac082.
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–8. Epub 2020/05/24.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. Epub 20130402.
   PubMed Web of Science ®Google Scholar
• Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23(29):7312–21. Epub 20050829.
   PubMed Web of Science ®Google Scholar
• Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, Mifsud W, Vujanić G, Sebire N, Le Bouc Y, et al. Gain of 1q as a prognostic biomarker in Wilms tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: a SIOP renal tumours biology consortium study. J Clin Oncol. 2016;34(26):3195–203. Epub 20160718.
   PubMed Web of Science ®Google Scholar
• Scott RH, Douglas J, Baskcomb L, Huxter N, Barker K, Hanks S, Craft A, Gerrard M, Kohler JA, Levitt GA, et al. Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat Genet. 2008;40(11):1329–34. Epub 20081005.
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA. 2007;104(50):20007–12. Epub 20071206.
   PubMed Web of Science ®Google Scholar
• Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. Biom J. 2010;52(1):70–84.
   PubMed Web of Science ®Google Scholar
• Sobecki M, Mrouj K, Colinge J, Gerbe F, Jay P, Krasinska L, Dulic V, Fisher D. Cell-cycle regulation accounts for variability in Ki-67 expression levels. Cancer Res. 2017;77(10):2722–34. Epub 20170310.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yuan X, Zhu W, Qian H, Xu W. SALL4: an emerging cancer biomarker and target. Cancer Lett. 2015;357(1):55–62. Epub 20141120.
   PubMed Web of Science ®Google Scholar
• Deisch J, Raisanen J, Rakheja D. Immunoexpression of SALL4 in Wilms tumors and developing kidney. Pathol Oncol Res. 2011;17(3):639–44. Epub 20110122.
   PubMed Web of Science ®Google Scholar
• Liu H, Tang C, Yang Y. Identification of nephrogenic therapeutic biomarkers of Wilms tumor using machine learning. J Oncol. 2021;2021:6471169. Epub 20210809.
   PubMed Web of Science ®Google Scholar
• Schweigert A, Fischer C, Mayr D, von Schweinitz D, Kappler R, Hubertus J. Activation of the Wnt/β-catenin pathway is common in Wilms tumor, but rarely through β-catenin mutation and APC promoter methylation. Pediatr Surg Int. 2016;32(12):1141–6. doi:10.1007/s00383-016-3970-6.
   PubMed Web of Science ®Google Scholar
• Tian X-M, Xiang B, Jin L-M, Mi T, Wang J-K, Zhanghuang C, Zhang Z-X, Chen M-L, Shi Q-L, Liu F, et al. Immune-related gene signature associates with immune landscape and predicts prognosis accurately in patients with Wilms tumour. Front Immunol. 2022;13:920666. Epub 20220912.
   PubMed Web of Science ®Google Scholar
• Tang F, Lu Z, Lei H, Lai Y, Lu Z, Li Z, Tang Z, Zhang J, He Z. DNA methylation data-based classification and identification of prognostic signature of children with Wilms tumor. Front Cell Dev Biol. 2021;9:683242. Epub 20211224.
   PubMedGoogle Scholar
• Huang G, Mao J. Identification of a 12-gene signature and hub genes involved in kidney wilms tumor via integrated bioinformatics analysis. Front Oncol. 2022;12:877796. Epub 20220411.
   PubMed Web of Science ®Google Scholar
• Shukrun R, Pode-Shakked N, Pleniceanu O, Omer D, Vax E, Peer E, Pri-Chen S, Jacob J, Hu Q, Harari-Steinberg O, et al. Wilms’ tumor blastemal stem cells dedifferentiate to propagate the tumor bulk. Stem Cell Rep. 2014;3(1):24–33. Epub 20140626.
   PubMed Web of Science ®Google Scholar
• Koziej P, Kluszczynska K, Hartman ML, Czyz M. Trametinib-resistant melanoma cells displaying MITFhigh/NGFRlow/IL-8low phenotype are highly responsive to alternating periods of drug withdrawal and drug rechallenge. Int J Mol Sci. 2023;24(9):7891. Epub 20230426.
   PubMed Web of Science ®Google Scholar
• Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, Tiede B, Romano R-A, DeCoste C, Mercatali L, et al. ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol. 2014;16(10):1004–15. Epub 20140921.
   PubMed Web of Science ®Google Scholar
• Newman EA, Chukkapalli S, Bashllari D, Thomas TT, Van Noord RA, Lawlor ER, Hoenerhoff MJ, Opipari AW, Opipari VP. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation. Cell Death Dis. 2017;8(12):3208. Epub 20171213.
   PubMedGoogle Scholar
• Nouruzi S, Ganguli D, Tabrizian N, Kobelev M, Sivak O, Namekawa T, Thaper D, Baca SC, Freedman ML, Aguda A, et al. ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. Nat Commun. 2022;13(1):2282. Epub 20220427.
   PubMed Web of Science ®Google Scholar
• Pode-Shakked N, Harari-Steinberg O, Haberman-Ziv Y, Rom-Gross E, Bahar S, Omer D, Metsuyanim S, Buzhor E, Jacob-Hirsch J, Goldstein RS, et al. Resistance or sensitivity of Wilms’ tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target. Oncogene. 2011;30(14):1664–80. Epub 20110117.
   PubMed Web of Science ®Google Scholar
• Xu T, Xie M, Jing X, Jiang H, Wu X, Wang X, Shu Y. Loss of miR-26b-5p promotes gastric cancer progression via miR-26b-5p-PDE4B/CDK8-STAT3 feedback loop. J Transl Med. 2023;21(1):77. Epub 20230203.
   PubMed Web of Science ®Google Scholar
• Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Fornari F, Zanesi N, Alder H, D'Elia G, Gramantieri L, et al. Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res. 2010;70(8):3140–9. Epub 20100413.
   PubMed Web of Science ®Google Scholar
• Candiello E, Reato G, Verginelli F, Gambardella G, D Ambrosio A, Calandra N, Orzan F, Iuliano A, Albano R, Sassi F, et al. MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis. Mol Oncol. 2023;17(7):1280–301. Epub 20230319.
   PubMed Web of Science ®Google Scholar
• Li PH, Kong XY, He YZ, Liu Y, Peng X, Li ZH, et al. Recent developments in application of single-cell RNA sequencing in the tumour immune microenvironment and cancer therapy. Mil Med Res. 2022;9(1):52.
   PubMed Web of Science ®Google Scholar